Bastiano Sanna
Director/Board Member bij Joslin Diabetes Center, Inc.
Vermogen: 13 M $ op 31-03-2024
Profiel
Bastiano Sanna is a Trustee at Joslin Diabetes Center, Inc. He previously served as the President & Chief Executive Officer at Semma Therapeutics, Inc. from 2018 to 2020.
He was also an Independent Director at Adicet Bio, Inc. from 2020 to 2023.
Prior to that, he held the position of Head-Stem Cell Transplant at Novartis International AG from 2014 to 2016 and Global Head-Strategic Planning at Novartis Institutes for Biomedical Research, Inc. from 2010 to 2016.
He served as the Chief Operating Officer at Magenta Therapeutics, Inc. from 2016 to 2018.
Additionally, he held a position as Executive VP, Head-Cell & Genetic Therapies at Vertex Pharmaceuticals, Inc. Dr. Sanna holds a doctorate degree from the University of Sassari.
Currently, he is a Trustee at Joslin Diabetes Center, Inc.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 08-05-2023 | 32 038 ( 0.01% ) | 13 M $ | 31-03-2024 | |
ADICET BIO INC
0.01% | 14-08-2023 | 5 900 ( 0.01% ) | 13 865 $ | 31-03-2024 |
Actieve functies van Bastiano Sanna
| Bedrijven | Functie | Begin |
|---|---|---|
Joslin Diabetes Center, Inc.
 Joslin Diabetes Center, Inc. Pharmaceuticals: MajorHealth Technology Joslin Diabetes Center, Inc. is a non-profit organization, which engages in the development of pharmaceuticals for diabetes. It provides adult care, pediatric care, eye care, and education programs and classes. The company was founded by Elliott P. Joslin in 1893 and is headquartered in Boston, MA. | Director/Board Member | 01-10-2023 |
Eerdere bekende functies van Bastiano Sanna
| Bedrijven | Functie | Einde |
|---|---|---|
| ADICET BIO, INC. | Director/Board Member | 07-11-2023 |
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01-02-2020 |
| MAGENTA THERAPEUTICS | Chief Operating Officer | 01-04-2018 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01-04-2016 |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01-04-2016 |
Opleiding van Bastiano Sanna
| University of Sassari | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| ADICET BIO, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Joslin Diabetes Center, Inc.
Joslin Diabetes Center, Inc. Pharmaceuticals: MajorHealth Technology Joslin Diabetes Center, Inc. is a non-profit organization, which engages in the development of pharmaceuticals for diabetes. It provides adult care, pediatric care, eye care, and education programs and classes. The company was founded by Elliott P. Joslin in 1893 and is headquartered in Boston, MA. | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Health Technology |
